Cargando…

Effects of dopexamine on the intestinal microvascular blood flow and leucocyte activation in a sepsis model in rats

INTRODUCTION: Dopexamine may be a therapeutic option to improve hepatosplanchnic perfusion in sepsis. To investigate this possibility, we administered dopexamine in an experimental sepsis model in rats. METHODS: This prospective, randomized, controlled laboratory study was conducted in 42 Wistar rat...

Descripción completa

Detalles Bibliográficos
Autores principales: Birnbaum, Jürgen, Klotz, Edda, Spies, Claudia D, Lorenz, Björn, Stuebs, Patrick, Hein, Ortrud Vargas, Gründling, Matthias, Pavlovic, Dragan, Usichenko, Taras, Wendt, Michael, Kox, Wolfgang J, Lehmann, Christian
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2006
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1750974/
https://www.ncbi.nlm.nih.gov/pubmed/16893450
http://dx.doi.org/10.1186/cc5011
_version_ 1782131397377392640
author Birnbaum, Jürgen
Klotz, Edda
Spies, Claudia D
Lorenz, Björn
Stuebs, Patrick
Hein, Ortrud Vargas
Gründling, Matthias
Pavlovic, Dragan
Usichenko, Taras
Wendt, Michael
Kox, Wolfgang J
Lehmann, Christian
author_facet Birnbaum, Jürgen
Klotz, Edda
Spies, Claudia D
Lorenz, Björn
Stuebs, Patrick
Hein, Ortrud Vargas
Gründling, Matthias
Pavlovic, Dragan
Usichenko, Taras
Wendt, Michael
Kox, Wolfgang J
Lehmann, Christian
author_sort Birnbaum, Jürgen
collection PubMed
description INTRODUCTION: Dopexamine may be a therapeutic option to improve hepatosplanchnic perfusion in sepsis. To investigate this possibility, we administered dopexamine in an experimental sepsis model in rats. METHODS: This prospective, randomized, controlled laboratory study was conducted in 42 Wistar rats. The animals were divided into three groups. Group 1 served as the control group (CON group). The animals in both groups 2 (LPS group) and 3 (DPX group) received an endotoxin (lipopolysaccharide from Escherichia coli – LPS) infusion (20 mg/kg for 15 minutes). DPX group additionally received dopexamine (0.5 μg/kg per minute over four hours). One half of the animals in each group underwent studies of intestinal microvascular blood flow (IMBF) using laser Doppler fluxmetry. In the other half an intravital microscopic evaluation of leucocyte-endothelial cell interaction in intestinal microcirculation was conducted. Functional capillary density (FCD) in the intestinal mucosa and in the circular as well as longitudinal muscle layer was estimated. RESULTS: One hour after endotoxin challenge, IMBF decreased significantly in LPS group to 51% compared with baseline (P < 0.05). In DPX group (endotoxin plus dopexamine) we found IMBF values significantly higher than those in LPS group (approximately at the level of controls). The impaired FCD following endotoxin challenge was improved by dopexamine in the longitudinal muscle layer (+33% in DPX group versus LPS group; P < 0.05) and in the circular muscle layer (+48% in DPX group versus LPS group; P < 0.05). In DPX group, dopexamine administration reduced the number of firmly adherent leucocytes (-31% versus LPS group; P < 0.05). Plasma levels of tumour necrosis factor-α were reduced by dopexamine infusion (LPS group: 3637 ± 553 pg/ml; DPX group: 1933 ± 201 pg/ml) one hour after endotoxin challenge. CONCLUSION: Dopexamine administration improved IMBF and FCD (markers of intestinal microcirculation) and reduced leucocyte activation (a marker of inflammation) in experimental sepsis.
format Text
id pubmed-1750974
institution National Center for Biotechnology Information
language English
publishDate 2006
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-17509742006-12-27 Effects of dopexamine on the intestinal microvascular blood flow and leucocyte activation in a sepsis model in rats Birnbaum, Jürgen Klotz, Edda Spies, Claudia D Lorenz, Björn Stuebs, Patrick Hein, Ortrud Vargas Gründling, Matthias Pavlovic, Dragan Usichenko, Taras Wendt, Michael Kox, Wolfgang J Lehmann, Christian Crit Care Research INTRODUCTION: Dopexamine may be a therapeutic option to improve hepatosplanchnic perfusion in sepsis. To investigate this possibility, we administered dopexamine in an experimental sepsis model in rats. METHODS: This prospective, randomized, controlled laboratory study was conducted in 42 Wistar rats. The animals were divided into three groups. Group 1 served as the control group (CON group). The animals in both groups 2 (LPS group) and 3 (DPX group) received an endotoxin (lipopolysaccharide from Escherichia coli – LPS) infusion (20 mg/kg for 15 minutes). DPX group additionally received dopexamine (0.5 μg/kg per minute over four hours). One half of the animals in each group underwent studies of intestinal microvascular blood flow (IMBF) using laser Doppler fluxmetry. In the other half an intravital microscopic evaluation of leucocyte-endothelial cell interaction in intestinal microcirculation was conducted. Functional capillary density (FCD) in the intestinal mucosa and in the circular as well as longitudinal muscle layer was estimated. RESULTS: One hour after endotoxin challenge, IMBF decreased significantly in LPS group to 51% compared with baseline (P < 0.05). In DPX group (endotoxin plus dopexamine) we found IMBF values significantly higher than those in LPS group (approximately at the level of controls). The impaired FCD following endotoxin challenge was improved by dopexamine in the longitudinal muscle layer (+33% in DPX group versus LPS group; P < 0.05) and in the circular muscle layer (+48% in DPX group versus LPS group; P < 0.05). In DPX group, dopexamine administration reduced the number of firmly adherent leucocytes (-31% versus LPS group; P < 0.05). Plasma levels of tumour necrosis factor-α were reduced by dopexamine infusion (LPS group: 3637 ± 553 pg/ml; DPX group: 1933 ± 201 pg/ml) one hour after endotoxin challenge. CONCLUSION: Dopexamine administration improved IMBF and FCD (markers of intestinal microcirculation) and reduced leucocyte activation (a marker of inflammation) in experimental sepsis. BioMed Central 2006 2006-08-07 /pmc/articles/PMC1750974/ /pubmed/16893450 http://dx.doi.org/10.1186/cc5011 Text en Copyright © 2006 Birnbaum et al.; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an open access article distributed under the terms of the Creative Commons Attribution License ( (http://creativecommons.org/licenses/by/2.0) ), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research
Birnbaum, Jürgen
Klotz, Edda
Spies, Claudia D
Lorenz, Björn
Stuebs, Patrick
Hein, Ortrud Vargas
Gründling, Matthias
Pavlovic, Dragan
Usichenko, Taras
Wendt, Michael
Kox, Wolfgang J
Lehmann, Christian
Effects of dopexamine on the intestinal microvascular blood flow and leucocyte activation in a sepsis model in rats
title Effects of dopexamine on the intestinal microvascular blood flow and leucocyte activation in a sepsis model in rats
title_full Effects of dopexamine on the intestinal microvascular blood flow and leucocyte activation in a sepsis model in rats
title_fullStr Effects of dopexamine on the intestinal microvascular blood flow and leucocyte activation in a sepsis model in rats
title_full_unstemmed Effects of dopexamine on the intestinal microvascular blood flow and leucocyte activation in a sepsis model in rats
title_short Effects of dopexamine on the intestinal microvascular blood flow and leucocyte activation in a sepsis model in rats
title_sort effects of dopexamine on the intestinal microvascular blood flow and leucocyte activation in a sepsis model in rats
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1750974/
https://www.ncbi.nlm.nih.gov/pubmed/16893450
http://dx.doi.org/10.1186/cc5011
work_keys_str_mv AT birnbaumjurgen effectsofdopexamineontheintestinalmicrovascularbloodflowandleucocyteactivationinasepsismodelinrats
AT klotzedda effectsofdopexamineontheintestinalmicrovascularbloodflowandleucocyteactivationinasepsismodelinrats
AT spiesclaudiad effectsofdopexamineontheintestinalmicrovascularbloodflowandleucocyteactivationinasepsismodelinrats
AT lorenzbjorn effectsofdopexamineontheintestinalmicrovascularbloodflowandleucocyteactivationinasepsismodelinrats
AT stuebspatrick effectsofdopexamineontheintestinalmicrovascularbloodflowandleucocyteactivationinasepsismodelinrats
AT heinortrudvargas effectsofdopexamineontheintestinalmicrovascularbloodflowandleucocyteactivationinasepsismodelinrats
AT grundlingmatthias effectsofdopexamineontheintestinalmicrovascularbloodflowandleucocyteactivationinasepsismodelinrats
AT pavlovicdragan effectsofdopexamineontheintestinalmicrovascularbloodflowandleucocyteactivationinasepsismodelinrats
AT usichenkotaras effectsofdopexamineontheintestinalmicrovascularbloodflowandleucocyteactivationinasepsismodelinrats
AT wendtmichael effectsofdopexamineontheintestinalmicrovascularbloodflowandleucocyteactivationinasepsismodelinrats
AT koxwolfgangj effectsofdopexamineontheintestinalmicrovascularbloodflowandleucocyteactivationinasepsismodelinrats
AT lehmannchristian effectsofdopexamineontheintestinalmicrovascularbloodflowandleucocyteactivationinasepsismodelinrats